Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Nov 06, 2021 12:24pm
206 Views
Post# 34095829

RE:RE:Did I lose the money in this?

RE:RE:Did I lose the money in this?

If Thomvest didn't see value of 4050 deals
on table in 2018, why would Thomvest continue to put money into this pig. Very easy to blame Pierre Laurin, Lynn Gagnon and John Moran but no way Thomvest throws out all of them and continues without some proof of value. It sure looks like they are playing the long game to gain sole control of 4050. Why else would they be here and continue funding? To get Ryplazim approved for patients? Not a chance.

DryBones wrote: Yeah,me too, but  I'm not blaming myself.  I was suckered by the lies, the misrepresentation of the value of the blood services, the research, the value of imminent approval of ryplazim and a whole lot of other failures.  There was a failure to be truthful, and those responsible have mostly left.  Now we see what this company really waz, a pipe dream con of morally incompetent schemers. 

This turned out to be a penny stock not worthy of listing on any exchange.  I'm glad Thomvest owns this pig in lipstick.  They deserve it, even though their credibility and integrity to the small time share holder is seriously and validly questioned.

 

<< Previous
Bullboard Posts
Next >>